Displaying drugs 8201 - 8225 of 9273 in total
TPCA-1
TPCA-1 is a selective inhibitor of human IκB kinase 2 (IKK-2).
Investigational
Matched Description: … TPCA-1 is a selective inhibitor of human IκB kinase 2 (IKK-2).[A253152] …
AQ-13
AQ-13 is an 4-aminoquinoline analog being investigated for the treatment of malaria.
Investigational
Matched Description: … AQ-13 is an 4-aminoquinoline analog being investigated for the treatment of malaria. …
AV-0113
AV-0113 consists of IL-12 secreting dendritic cells loaded with autologous tumor lysate.
Investigational
Matched Description: … AV-0113 consists of IL-12 secreting dendritic cells loaded with autologous tumor lysate. …
Irpagratinib
Irpagratinib (ABSK011) is a highly selective inhibitor of fibroblast growth factor receptor (FGFR) 4.
Investigational
Matched Description: … Irpagratinib (ABSK011) is a highly selective inhibitor of fibroblast growth factor receptor (FGFR) 4. …
AVI-4065
AVI-4065, a phosphorodiamidate Morpholino oligomer (PMO), is an investigational antisense HCV drug. It was developed by Sarepta Therapeutics, Inc. After phase II trials it was cancelled due to lack of potency.
Investigational
Matched Description: … After phase II trials it was cancelled due to lack of potency. [L2917] …
Q-Derp1
Q-Derp1 is developed by Cytos Biotechnology as an immunodrug. It is an antigen for the prevention of various major chronic diseases. Derp1 is the dominant allergic protein found in dust mite feces.
Investigational
Matched Description: … It is an antigen for the prevention of various major chronic diseases. …
NXN-188
NXN-188 is a first-in-class, dual-action small molecule incorporating both neuronal nitric oxide synthase (nNOS) inhibition and 5-HT agonism that is being developed for the treatment of acute migraine.
Investigational
Matched Description: … nitric oxide synthase (nNOS) inhibition and 5-HT agonism that is being developed for the treatment of …
Talsupram
Talsupram is a selective norepinephrine reuptake inhibitor (NRI). It was under research for the treatment of depression in 1960 and 1970 but it was never marketed. Talsupram presents a similar structure to citalopram.
Experimental
Matched Description: … It was under research for the treatment of depression in 1960 and 1970 but it was never marketed. …
Clinafloxacin
Clinafloxacin is a fluoroquinolone antibacterial currently under research. It has been proven to present good antibiotic properties. However, its approval and release have been halted due to the presence of serious side effects.
Investigational
Matched Description: … However, its approval and release have been halted due to the presence of serious side effects. …
USL-311
USL-311 is under investigation in clinical trial NCT02765165 (Phase 1/2 Study of USL311 Alone and in Combination With Lomustine in Subjects With Advanced Solid Tumors and Relapsed/Recurrent Glioblastoma Multiforme (GBM)).
Investigational
Matched Description: … USL-311 is under investigation in clinical trial NCT02765165 (Phase 1/2 Study of USL311 Alone and in …
Ligufalimab
Ligufalimab is a humanized immunoglobulin G4 (IgG4) monoclonal antibody targeting leukocyte surface antigen CD47. It is under investigation in clinical trial NCT04900350 (A Trial of AK117 (Anti-cd47) in Patients With Myelodysplastic Syndrome).
Investigational
Matched Description: … It is under investigation in clinical trial NCT04900350 (A Trial of AK117 (Anti-cd47) in Patients With …
TAK-754
TAK-754 is an adeno-associated virus serotype 8 vector (AAV8) expressing B domain deleted codon optimized factor VIII. Developed by Takeda, it is being investigated for the treatment of hemophilia A.
Investigational
Matched Description: … Developed by Takeda, it is being investigated for the treatment of hemophilia A.[A259831] …
Retatrutide
Retatrutide is under investigation in clinical trial NCT06354660 (Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)).
Investigational
Matched Description: … Retatrutide is under investigation in clinical trial NCT06354660 (Effect of Retatrutide Compared With …
Fenbendazole
Fenbendazole is a benzimidazole that presents a wide spectrum anthelmintic effect. It is used against a number of gastrointestinal parasites including giardia, roundworms, hookworms, whipworms, the Taenia genus of tapeworms, pinworms, aelurostrongylus, paragonimiasis, strongyles, and Strongyloides. Fenbendazole is approved to be administered under veterinary to sheep, cattle, horses, fish, dogs,...
Vet approved
Matched Description: … It is used against a number of gastrointestinal parasites including giardia, roundworms, hookworms, whipworms ... , the Taenia genus of tapeworms, pinworms, aelurostrongylus, paragonimiasis, strongyles, and Strongyloides …
SYNB1353
SYNB1353 is a strain of the probiotic bacteria Escherichia coli (E. coli) type Nissle and an engineered probiotic drug. Developed by Synlogic Operating Company, Inc., SYNB1353 is being investigated for the treatment of homocystinuria. It is designed to consume methionine in the gastrointestinal tract to prevent its absorption and conversion...
Investigational
Matched Description: … SYNB1353 is a strain of the probiotic bacteria _Escherichia coli_ (_E. coli_) type Nissle and an engineered ... A258833] Developed by Synlogic Operating Company, Inc., SYNB1353 is being investigated for the treatment of …
GS030-DP
GS030-DP is an optogenetic gene therapy being investigated for the treatment of retinitis pigmentosa. It targets retinal ganglion cells that encodes a light-sensitive channelrhodopsin, ChrimsonR-tdTomato (ChR-tdT), delivered by an AAV2.7m8 vector. It is a component of GS030, an investigational optogenetic treatment, in combination with a medical device GS030-MD.[A259816, L46701]
Investigational
Matched Description: … GS030-DP is an optogenetic gene therapy being investigated for the treatment of retinitis pigmentosa. ... It is a component of GS030, an investigational optogenetic treatment, in combination with a medical device …
P54
P54 reduces the inflammation associated with cancer/tumors, Crohn's disease, inflammatory bowel disease, osteoarthritis, and ulcerative colitis. It inhibits the induction of the enzyme NFkB, thereby inhibiting downstream inflammatory genes such as COX II and iNOS.
Investigational
Matched Description: … It inhibits the induction of the enzyme NFkB, thereby inhibiting downstream inflammatory genes such as …
Talnetant
Talnetant (SB-223,412) is a neurokinin 3 receptor antagonist developed by GlaxoSmithKline, which is being researched for several different functions, primarily for irritable bowel syndrome and as a potential antipsychotic drug for the treatment of schizophrenia.
Investigational
Matched Description: … functions, primarily for irritable bowel syndrome and as a potential antipsychotic drug for the treatment of …
Zalutumumab
Zalutumumab is a fully human IgG1 monoclonal antibody designed to bind with selectivity to the epidermal growth factor receptor (EGFR). Zalutumumab has been investigated for the treatment of Squamous Cell Cancer and Head and Neck Cancer.
Investigational
Matched Description: … Zalutumumab has been investigated for the treatment of Squamous Cell Cancer and Head and Neck Cancer. …
Efpeglenatide
Efpeglenatide is under investigation in clinical trial NCT03713684 (Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Alone or in Combination With Oral Antidiabetic Drug(s)).
Investigational
Matched Description: … Efpeglenatide is under investigation in clinical trial NCT03713684 (Efficacy and Safety of Efpeglenatide …
Perfluorodecalin
Perfluorodecalin is under investigation in clinical trial NCT03668665 (Influencing Wound Healing Through the Application of Hyaluronic Acid With Perfluorodecalin and Physalis Angulata Extract After Split Skin Removal From the Thigh - a Study in "Split Wound Design").
Investigational
Matched Description: … under investigation in clinical trial NCT03668665 (Influencing Wound Healing Through the Application of …
Dialyzable leukocyte extract
Transferon is comprised of several peptides mixed from human dialyzable leucocyte extracts and acts as an immunomodulator. It is thought to have widespread effects on the immune system, and effective in treating infections and immunological issues.
Investigational
Matched Description: … Transferon is comprised of several peptides mixed from human dialyzable leucocyte extracts and acts as …
ABBV-514
ABBV-514 is in development for the treatment of non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC) as a single agent and in combination with a PD-1 inhibitor.
Investigational
Matched Description: … ABBV-514 is in development for the treatment of non-small cell lung cancer (NSCLC) and head and neck …
VX-702
VX-702 is a small molecule investigational oral anti-cytokine therapy for treatment of inflammatory diseases, specifically rheumatoid arthritis (RA). It acts as a p38 MAP kinase inhibitor. In the future, VX-702 may be investigated for combination with methotrexate, a commonly used therapy for RA.
Investigational
Matched Description: … VX-702 is a small molecule investigational oral anti-cytokine therapy for treatment of inflammatory diseases …
Batroxobin
Batroxobin is a defibrinogenating hemostatic agent derived from the venom of a pit viper, Bothrops atrox moojeni. In addition to batroxobin, the venom of Bothrops atrox has a composition of 10.2% neutral carbohydrate. Batroxobin is a serine protease, which cleaves the 16 Arginine - 17 Glycine bond in fibrinogen. The...
Experimental
Matched Description: … In addition to batroxobin, the venom of Bothrops atrox has a composition of 10.2% neutral carbohydrate ... The MW of batroxobin is approximately 43,000 g/mol-1, and it contains 231 amino acids. ... Batroxobin is a defibrinogenating hemostatic agent derived from the venom of a pit viper, Bothrops atrox …
Displaying drugs 8201 - 8225 of 9273 in total